|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide |
Synonyms ![]() |
AZD4901 | MLE4901 |
Comments |
AZD2624 is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AstraZeneca as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase 2 study for the latter indication was reported in April 2017 [4]. A total of eight analogues are disclosed in the AstraZeneca composition of matter filing [5], |
Database Links ![]() |
|
CAS Registry No. | 941690-55-7 |
GtoPdb PubChem SID | 178102400 |
PubChem CID | 23649245 |
Search Google for chemical match using the InChIKey | QYTBBBAHNIWFOD-NRFANRHFSA-N |
Search Google for chemicals with the same backbone | QYTBBBAHNIWFOD |
Search UniChem for chemical match using the InChIKey | QYTBBBAHNIWFOD-NRFANRHFSA-N |
Search UniChem for chemicals with the same backbone | QYTBBBAHNIWFOD |